Basic info
Industry
biotechnology research
Sectors
Biotechnology
biotechnology
Allogeneic EBV CAR T-cell platform
regenerative medicine
CTLs
cytotoxic T lymphocytes
Allogeneic CD19 CAR T
oncology
EBV lymphoma
allogeneic
cell therapy
immunotherapy
Atara
EBV
PTLD
immuno-oncology
Epstein-Barr virus
oncoviruses
secondary lymphoma
immunology
off the shelf
autoimmune diseases
T-cells
Cytomegalovirus
stem cell transplant
nasopharyngeal carcinoma
bone marrow transplant
post-transplant lymphoproliferative disorder
CAR T
solid organ transplant
multiple sclerosis
MS
lymphoma
secondary malignancy
gene therapy
progressive multiple sclerosis
CMV
solid tumors
lymphoproliferative disorders
hematology
Health Care
Atara Bio
Therapeutics
cancer
Allogeneic CAR T-cell therapies
ATRA
Date founded
2012
Funding rounds raised
Total raised
$39M
from 9 investors over 9 rounds
A
Atara Biotherapeutics raised $14M on January 10, 2014
Investors: Celgene, Domain Associates, Kleiner Perkins and DAG Ventures
A
Atara Biotherapeutics raised $39M on December 17, 2013
Investors: DAG Ventures, Kleiner Perkins, Celgene and Domain Associates
A
Atara Biotherapeutics raised $1M on March 31, 2013
Investors: Domain Associates